(Q37681569)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20102305%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

review article

1 reference

title

Inhaled corticosteroids in chronic obstructive pulmonary disease: a review (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20102305%20AND%20SRC:MED&resulttype=core&format=json

chronic obstructive pulmonary disease

17 January 2020

main subject

0 references

author

Eef Telenga

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20102305%20AND%20SRC:MED&resulttype=core&format=json

Hubertus Adrianus Marie Kerstjens

17 January 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20102305%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

3

Dirkje S Postma

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20102305%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

author name string

Nick H Ten Hacken

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20102305%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Maarten van den Berge

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20102305%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

language of work or name

English

0 references

publication date

1 February 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20102305%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Pharmacotherapy

17 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20102305%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20102305%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20102305%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

page(s)

405-421

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20102305%20AND%20SRC:MED&resulttype=core&format=json

Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study

17 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Smoking and lung function of Lung Health Study participants after 11 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Methodological issues in therapeutic trials of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

The influence of COPD on health-related quality of life independent of the influence of comorbidity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Impact of preventing exacerbations on deterioration of health status in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Definitions of exacerbations: does it really matter in clinical trials on COPD?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

The burden of COPD in The Netherlands: results from the Confronting COPD survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Costs of chronic bronchitis and COPD: a 1-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Epidemiology and costs of chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Frequency of self-reported COPD exacerbation and airflow obstruction in five Latin American cities: the Proyecto Latinoamericano de Investigacion en Obstruccion Pulmonar (PLATINO) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Oral or IV prednisolone in the treatment of COPD exacerbations: a randomized, controlled, double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Anti-inflammatory effects of combined budesonide/formoterol in COPD exacerbations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD. A double-blind, randomised, non-inferiority, parallel-group, multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

The role of nebulised budesonide in the treatment of exacerbations of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

The impact of COPD on lung health worldwide: epidemiology and incidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Relation of ventilatory impairment and of chronic mucus hypersecretion to mortality from obstructive lung disease and from all causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Chronic Obstructive Pulmonary Disease, inflammation and co-morbidity--a common inflammatory phenotype?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Inhaled corticosteroids and risk of lung cancer among patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Cellular and structural bases of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

The nature of small-airway obstruction in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Comparison of the structural and inflammatory features of COPD and asthma. Giles F. Filley Lecture.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Increased number of B-cells in bronchial biopsies in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Cigarette smoke-induced emphysema: A role for the B cell?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Ongoing airway inflammation in patients with COPD who do not currently smoke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Change in inflammation in out-patient COPD patients from stable phase to a subsequent exacerbation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Long-term effects of budesonide on inflammatory status in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Tissue inhibitor of metalloproteinases and collagenase inhibitory activity in lung secretions from patients with chronic obstructive bronchitis: effect of corticosteroid treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Inhaled corticosteroids reduce neutrophilic bronchial inflammation in patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Effects of fluticasone propionate on inflammatory cells in COPD: an ultrastructural examination of endobronchial biopsy tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

In patients with chronic bronchitis a four week trial with inhaled steroids does not attenuate airway inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

The effect of inhaled corticosteroids on bronchoalveolar lavage cells and IL-8 levels in stable COPD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Elastase inhibitors of sputum sol phase: variability, relationship to neutrophil elastase inhibition, and effect of corticosteroid treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Correlation between change in pulmonary function and suppression of reactive nitrogen species production following steroid treatment in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Aerosolized beclomethasone in chronic bronchitis. Improved pulmonary function and diminished airway inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Effects of fluticasone propionate inhalation on levels of arachidonic acid metabolites in patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Effects of fluticasone propionate in COPD patients with bronchial hyperresponsiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Effect of corticosteroids on sputum sol-phase protease inhibitors in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Decreased histone deacetylase activity in chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Low-dose theophylline enhances the anti-inflammatory effects of steroids during exacerbations of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Mechanisms of bronchial hyperreactivity in asthma and chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Bronchial reactivity to inhaled histamine and annual rate of decline in FEV1 in male smokers and ex-smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Methacholine reactivity predicts changes in lung function over time in smokers with early chronic obstructive pulmonary disease. The Lung Health Study Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

The importance of serum IgE for level and longitudinal change in airways hyperresponsiveness in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Effects of inhaled budesonide on spirometric values, reversibility, airway responsiveness, and cough threshold in smokers with chronic obstructive lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Short- and long-term efficacy of fluticasone propionate in subjects with early signs and symptoms of chronic obstructive pulmonary disease. Results of the DIMCA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Lung function and symptom improvement with fluticasone propionate/salmeterol and ipratropium bromide/albuterol in COPD: response by beta-agonist reversibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Characteristics of COPD phenotypes classified according to the findings of HRCT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Bronchodilator reversibility, airway eosinophilia and anti-inflammatory effects of inhaled fluticasone in COPD are not related

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Prediction of treatment-response to inhaled corticosteroids by mannitol-challenge test in COPD. A proof of concept

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Ligand-independent activation of the glucocorticoid receptor by beta2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Biochemical interaction between effects of beclomethasone dipropionate and salbutamol or formoterol in sputum cells from mild to moderate asthmatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Interaction between glucocorticoids and beta2 agonists on bronchial airway smooth muscle cells through synchronised cellular signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

A population based case-control study of cataract and inhaled corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Budesonide and the risk of pneumonia: a meta-analysis of individual patient data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

The association of inhaled corticosteroid use with serum glucose concentration in a large cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Purpura and dermal thinning associated with high dose inhaled corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Association between CRHR1 polymorphism and improved lung function in response to inhaled corticosteroid in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

The lung health study: airway responsiveness to inhaled methacholine in smokers with mild to moderate airflow limitation. The Lung Health Study Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

From COPD to chronic systemic inflammatory syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

Complex chronic comorbidities of COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903510628

10.1517/14656560903510628

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20102305%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference